Biotech Values

[DewDiligence]

Update on Copaxone patent case (from MNTA’s 3Q10 CC):

• As reported in the public court pleadings, NVS/MNTA intend to pursue four arguments: i) indefiniteness of Teva’s patents; ii) invalidity of Teva’s patents due to obviousness and/or double patenting; ii) non-infringement by NVS/MNTA’s product; and iv) inequitable conduct.

• According to Craig Wheeler, the Court’s denial of NVS/MNTA’s motion for a summary judgment on patent indefiniteness does not impair NVS/MNTA’s ability to argue this point at trial.

• The Court consolidated Teva’s suit against NVS/MNTA and Teva’s suit against Mylan, which will delay the start of the trial until 1H11.